Product Name	Elotuzumab (anti-SLAMF7) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to SLAMF7, >95%, high purity, Human IgG1
Synonyms	Recombinant Elotuzumab Antibody \| Elotuzumab \| HuLuc 63 \| PDL 063 \| BMS 901608 \| Elotuzumab (anti-SLAMF7) \| BMS-901608 \| PDL063 \| HuLuc63 \| Empliciti \| 19A antibody \| 19A24 protein antibody \| CD 319 antibody \| CD2 like receptor activating cytotoxic cells
Specifications & Purity	ExactAb™, Validated, Carrier Free, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host species	Human
Specificity	SLAMF7
Application	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Recombinant, Validated
Action Type	INHIBITOR
Mechanism of action	Antibody of CS1 (CD319)
Product Description	Elotuzumab is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity. Purity >95% (SDS-PAGE&SEC) Endotoxin Level<0.01EU/μg

Product Properties

Antibody Type	Primary antibody
Clonality	Recombinant
Isotype	Human IgG1
Light Chain Type	kappa
SDS-PAGE	27.1 kDa (Light Chain) & 52.3 kDa (Heavy Chain), under reducing conditions; 173.0 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Source	CHO supernatant
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	915296-00-3

IMGT/mAb-DB

Wikipedia

Certificates

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0303033	Certificate of Analysis	Mar 08, 2024	Ab169272
ZJ24F0303032	Certificate of Analysis	Mar 08, 2024	Ab169272
ZJ24F0303031	Certificate of Analysis	Mar 08, 2024	Ab169272

References

1. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG et al.. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.. Blood, 112 (4): (1329-37). [PMID:17906076] [10.1021/op500134e]
2. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y et al.. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.. Clin Cancer Res, 14 (9): (2775-84). [PMID:18451245] [10.1021/op500134e]
3. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R et al.. (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.. Mol Cancer Ther, 8 (9): (2616-24). [PMID:19723891] [10.1021/op500134e]
4. Veillette A, Guo H. (2013) CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.. Crit Rev Oncol Hematol, 88 (1): (168-77). [PMID:23731618] [10.1021/op500134e]

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Elotuzumab (anti-SLAMF7) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to SLAMF7, >95%, high purity, Human IgG1, Antibody of CS1 (CD319)

Basic Description